GLP-1, RAs, Glucagon-like peptide-1, receptor agonists
Companies should not market compounded GLP-1 drugs as FDA-approved generics or as clinically proven equivalents to approved medications
This reveals whether semaglutide alone, tirzepatide, or dual-compound therapy aligns best with your geneticsknowledge that becomes even more valuable when managing weight during HRT, since hormonal stability plus genetically-matched GLP-1 therapy creates your most effective protocol
note that these absorption rates are for cyanocobalamin)
These positive effects decline with age because the concentration of GHK-Cu in the body decreases
Implications for Practice Due to the established connection between GLP-1 agonists and DR, optometrists should err on the side of caution and be in contact with primary care physicians on whether GLP-1/gastric inhibitory polypeptide (GIP) agonists should be prescribed in patients who have existing DR